22nd Century Group (XXII) Stock Soars 110.04% on FDA Compliance

22nd Century Group (XXII) stock surged 110.04% in pre-market trading on July 17, 2025, marking a significant rise in its share price.

22nd Century Group has recently expanded its partnerships with multiple tobacco brands to promote its VLN-based reduced nicotine content products. This strategic move aims to increase the availability and awareness of VLN® reduced nicotine cigarettes, which contain 95% less nicotine than conventional cigarettes. The company's efforts align with the FDA's proposed new standard to limit nicotine content in cigarettes, positioning 22nd Century as a leader in compliance and innovation within the regulatory landscape.

The company's CEO, Larry Firestone, highlighted the potential public health benefits of these partnerships, emphasizing the significance of providing consumers with choices to manage their nicotine consumption responsibly. The VLN® cigarettes are the only FDA-authorized combustible products that meet the new nicotine standard, supported by extensive clinical research.

Despite a challenging first quarter, 22nd Century Group's stock performance reflects investor confidence in its ability to capitalize on the growing market interest in harm reduction and the FDA's proposed nicotine standard. The company's strategic moves and partnerships suggest a positive outlook for the future, although reliance on regulatory changes from the FDA poses a risk if the proposed standards are modified or delayed.